A Multicenter, Randomized, Open-labeled Trial: Efficacy of Once-daily vs. Twice-daily Double-Dose Rabeprazole on Refractory Gastroesophageal Reflux Disease-Related Symptoms and Quality of Life

Conclusion In patients with refractory GERD, there was no significant difference in GOS, PSQI, or recurrence rate between the groups. With regards to sub-scores of SF-8, however, the 10 mg twice-daily RPZ group might be potentially effective.
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research